TG Therapeutics Stock Soars Nearly 15% After Topping Deloitte's Fast 500 and Raising Revenue Outlook

GuruFocus11-22 01:11

TG Therapeutics (TGTX, Financial) is making waves in the biotech sector as the fastest-growing company in North America, earning the #1 position on Deloitte's Technology Fast 500 list. The recognition...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2485441834?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-22 01:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2485441834","market":"hk","top_or_hot":-1,"title":"TG Therapeutics Stock Soars Nearly 15% After Topping Deloitte's Fast 500 and Raising Revenue Outlook","media":"GuruFocus","content":"<div>\n<p>TG Therapeutics (TGTX, Financial) is making waves in the biotech sector as the fastest-growing company in North America, earning the #1 position on Deloitte's Technology Fast 500 list. The recognition...</p>\n\n<a href=\"https://www.gurufocus.com/news/2612538/tg-therapeutics-stock-soars-nearly-15-after-topping-deloittes-fast-500-and-raising-revenue-outlook\">Source Link</a>\n\n</div>\n","source":"gurufocus_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TG Therapeutics Stock Soars Nearly 15% After Topping Deloitte's Fast 500 and Raising Revenue Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTG Therapeutics Stock Soars Nearly 15% After Topping Deloitte's Fast 500 and Raising Revenue Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-22 01:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.gurufocus.com/news/2612538/tg-therapeutics-stock-soars-nearly-15-after-topping-deloittes-fast-500-and-raising-revenue-outlook><strong>GuruFocus</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>TG Therapeutics (TGTX, Financial) is making waves in the biotech sector as the fastest-growing company in North America, earning the #1 position on Deloitte's Technology Fast 500 list. The recognition...</p>\n\n<a href=\"https://www.gurufocus.com/news/2612538/tg-therapeutics-stock-soars-nearly-15-after-topping-deloittes-fast-500-and-raising-revenue-outlook\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FAST","symbol_name":"快扣","start_time":0,"source_url":"https://www.gurufocus.com/news/2612538/tg-therapeutics-stock-soars-nearly-15-after-topping-deloittes-fast-500-and-raising-revenue-outlook","article_id":"2485441834","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2485441834","pubTimestamp":1732209096,"sourceInfo":{"source_id":"gurufocus_highlight","name":"GuruFocus"},"weMediaInfo":null,"summary":"TG Therapeutics (TGTX, Financial) is making waves in the biotech sector as the fastest-growing company in North America, earning the #1 position on Deloitte's Technology Fast 500 list. The recognition","collect":0,"end_time":0,"defaultTopTitle":"gurufocus.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"FAST":"快扣","TG":"特里迪加","TGTX":"TG Therapeutics Inc."},"translate_title":"TG Therapeutics股价在超越德勤500强并上调收入前景后飙升近15%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FAST":1,"TG":1,"TGTX":1},"content_text":"TG Therapeutics (TGTX, Financial) is making waves in the biotech sector as the fastest-growing company in North America, earning the #1 position on Deloitte's Technology Fast 500 list. The recognition underscores the meteoric rise of BRIUMVI®, its breakthrough treatment for relapsing multiple sclerosis, approved in late 2022. CEO Michael S. Weiss lauded the team's efforts and emphasized the company's commitment to advancing treatment options for multiple sclerosis patients, a sentiment echoed by its 230% year-over-year growth in Q3 2024 revenue.Fueled by robust market uptake, TG Therapeutics reported $83.3 million in Q3 2024 U.S. BRIUMVI revenue—a 15% increase from the previous quarter—and raised its full-year revenue guidance to $300–305 million. With over 92% of patients showing no disability progression after five years, BRIUMVI continues to redefine therapeutic benchmarks. The company's innovative pipeline, including a subcutaneous version of BRIUMVI and novel CAR-T cell therapies, signals its intent to dominate the autoimmune treatment landscape.Investors are taking notice as TG Therapeutics combines clinical excellence with operational prowess, ensuring sustained momentum into 2025. With a robust cash position of $341 million, strategic partnerships like FUJIFILM Diosynth Biotechnologies, and ongoing developments in autoimmune therapies, TG Therapeutics is not just meeting expectations—it's reshaping them.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2485441834"}